Yayınlanmış 1 Ocak 2013
| Sürüm v1
Dergi makalesi
Açık
miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells
Oluşturanlar
- 1. Izmir Inst Technol, Dept Mol Biol & Genet, TR-35430 Izmir, Turkey
- 2. Ege Univ, Sch Med, Dept Med Biol, Izmir, Turkey
Açıklama
Purpose: In this study we examined the expression levels of miR-17 which possesses oncogenic activities through downregulation of CDKN1A, p21 and E2F1 tumor suppressor genes, in imatinib sensitive and resistant chronic myeloid leukemia (CML) cells. On the other hand, we also determined the expression levels of miR-17 in response to tyrosine kinase inhibitors imatinib, nilotinib and dasatinib used for the treatment of CML.
Dosyalar
bib-aa963312-d35f-440b-9a38-ff33cb982f82.txt
Dosyalar
(185 Bytes)
| Ad | Boyut | Hepisini indir |
|---|---|---|
|
md5:c7fcd348bc251465c03e10f797331921
|
185 Bytes | Ön İzleme İndir |